Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by GORDON B MILLS and JOHN N WEINSTEIN.
GORDON B MILLS
Connection Strength
3.222
JOHN N WEINSTEIN
  1. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31; 511(7511):543-50.
    View in: PubMed
    Score: 0.508
  2. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014 Mar 20; 507(7492):315-22.
    View in: PubMed
    Score: 0.492
  3. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9.
    View in: PubMed
    Score: 0.472
  4. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29; 474(7353):609-15.
    View in: PubMed
    Score: 0.412
  5. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19; 171(3):540-556.e25.
    View in: PubMed
    Score: 0.159
  6. A curated census of autophagy-modulating proteins and small molecules: candidate targets for cancer therapy. Autophagy. 2014 Jul; 10(7):1316-26.
    View in: PubMed
    Score: 0.126
  7. MODULATION OF AUTOPHAGY AND ITS POTENTIAL FOR CANCER THERAPY. Drugs Future. 2011; 36(12).
    View in: PubMed
    Score: 0.099
  8. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73.
    View in: PubMed
    Score: 0.058
  9. RPPA SPACE: an R package for normalization and quantitation of Reverse-Phase Protein Array data. Bioinformatics. 2022 11 15; 38(22):5131-5133.
    View in: PubMed
    Score: 0.057
  10. Integrated transcriptomic-genomic tool Texomer profiles cancer tissues. Nat Methods. 2019 05; 16(5):401-404.
    View in: PubMed
    Score: 0.044
  11. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2018 08 09; 174(4):1033.
    View in: PubMed
    Score: 0.042
  12. Predicting high-risk endometrioid carcinomas using proteins. Oncotarget. 2018 Apr 13; 9(28):19704-19715.
    View in: PubMed
    Score: 0.041
  13. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep. 2018 04 03; 23(1):239-254.e6.
    View in: PubMed
    Score: 0.041
  14. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018 04 09; 33(4):690-705.e9.
    View in: PubMed
    Score: 0.041
  15. Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. Cancer Res. 2017 11 01; 77(21):e51-e54.
    View in: PubMed
    Score: 0.040
  16. A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell. 2017 06 12; 31(6):820-832.e3.
    View in: PubMed
    Score: 0.039
  17. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017 03 13; 31(3):411-423.
    View in: PubMed
    Score: 0.038
  18. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.
    View in: PubMed
    Score: 0.035
  19. TransVar: a multilevel variant annotator for precision genomics. Nat Methods. 2015 Nov; 12(11):1002-3.
    View in: PubMed
    Score: 0.035
  20. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015 Aug; 5(8):860-77.
    View in: PubMed
    Score: 0.034
  21. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25; 372(26):2481-98.
    View in: PubMed
    Score: 0.034
  22. Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2015 Jan 28; 6:4852.
    View in: PubMed
    Score: 0.033
  23. Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics. 2015 Mar 15; 31(6):912-8.
    View in: PubMed
    Score: 0.032
  24. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014 Aug 14; 158(4):929-944.
    View in: PubMed
    Score: 0.032
  25. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 2014 Jul; 32(7):644-52.
    View in: PubMed
    Score: 0.032
  26. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun. 2014 May 29; 5:3887.
    View in: PubMed
    Score: 0.031
  27. The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10; 155(2):462-77.
    View in: PubMed
    Score: 0.030
  28. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013 Oct; 45(10):1113-20.
    View in: PubMed
    Score: 0.030
  29. TCPA: a resource for cancer functional proteomics data. Nat Methods. 2013 Nov; 10(11):1046-7.
    View in: PubMed
    Score: 0.030
  30. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90.
    View in: PubMed
    Score: 0.028
  31. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012 Sep; 2(9):798-811.
    View in: PubMed
    Score: 0.028
  32. Exposing the cancer genome atlas as a SPARQL endpoint. J Biomed Inform. 2010 Dec; 43(6):998-1008.
    View in: PubMed
    Score: 0.025
  33. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther. 2010 Feb; 9(2):257-67.
    View in: PubMed
    Score: 0.023
  34. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol. 2008 Mar; 108(3):652-7.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.